Roche Aktie

272,05 EUR -1,90 EUR -0,69 %

08:40:01

FSE

255,44 CHF +0,93 CHF +0,37 %

09:01:06

BRX

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.215,92 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

07:00Roche Holding AGData show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

24.09.25Roche Holding AGRoche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

22.09.25Roche Holding AGPositive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

19.09.25Roche Holding AGCHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

18.09.25PR NewswireRoche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

18.09.25Roche Holding AGRoche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

16.09.25PR NewswireRoche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

05.09.25PR NewswireRoche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

05.09.25Roche Holding AGNew data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

04.09.25Roche Holding AGRoche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

30.08.25Roche Holding AGRoche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

25.08.25Roche Holding AGRoche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

01.08.25Roche Holding AGRoche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

28.07.25Roche Holding AGRoche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

25.07.25Roche Holding AGRoche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU

24.07.25PR NewswireRoche Diagnostics showcases science-driven leadership and innovation at ADLM 2025

24.07.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025

23.07.25Roche Holding AGEuropean Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

22.07.25Roche Holding AGRoche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

21.07.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

30.06.25Roche Holding AGChanges to the Roche Enlarged Corporate Executive Committee

23.06.25Roche Holding AGEarly data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

20.06.25Roche Holding AGRoche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

16.06.25GlobeNewswireRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

16.06.25Roche Holding AGRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

15.06.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

15.06.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

04.06.25GlobeNewswireRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

04.06.25Roche Holding AGRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

03.06.25Roche Holding AGRoche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

03.06.25GlobeNewswireRoche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

31.05.25Roche Holding AGNew data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

31.05.25GlobeNewswireNew data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

30.05.25GlobeNewswireRoche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

30.05.25Roche Holding AGRoche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

23.05.25GlobeNewswireCHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

23.05.25Roche Holding AGRoche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

23.05.25GlobeNewswireRoche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.